Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Pregnancy-associated plasma protein-A (PAPP-A) is involved in the development of autosomal dominant polycystic kidney disease. In preclinical mouse models, the anti-PAPP-A monoclonal antibody ABBV-CLS-628 was shown to reduce kidney volume and improve eGFR. Dr Georgios Koukos (Calico Life Sciences, CA, USA) presented data on ABBV-CLS-628 in 3 different mouse models, including a fast-progressing non-orthologous disease model, an inducible and fast-progressing disease model, and a slow-progressing orthologous disease model [1]. Mice in the 3 models were treated weekly with either ABBV-CLS-628 or an isotype control antibody for a total of 22, 12, and 62 weeks, respectively, and plasma and kidney tissues were collected for analysis. In the fast-progressing non-orthologous disease model, ABBV-CLS-628 led to a 52% decrease in total kidney volume (P<0.001) after 21 weeks of treatment, as well as an improvement in eGFR after 18 weeks of treatment (P=0.005...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 11 June 202522 August 2025